Hsa-miR-181a-5p, hsa-miR-182-5p, and hsa-miR-26a-5p as potential biomarkers for BCR-ABL1 among adult chronic myeloid leukemia treated with tyrosine kinase inhibitors at the molecular response

Aliza Mohd Yacob1*, Nor Asiah Muhamad2, Kian Meng Chang3, Hamidah Akmal Hisham4, Yuslina Mat Yusoff1 and Latifah Ibrahim5

Abstract

Background: Tyrosine kinase inhibitors (TKIs) as first-line therapy for Chronic Myeloid Leukemia (CML) show a high success rate. However, a low number of patients with long-term treatment-free remission (TFR) were observed. Molecular relapse after imatinib discontinuation occurred at 50% at 24 months, with 80% occurrence within the first 6 months. One of the reasons for relapse is untimely TKIs discontinuation caused by large errors from estimates at very low-level or undetectable disease, thus warranting new biomarkers for CML.

Methods: Next Generation Sequencing (NGS) was used to identify microRNAs (miRNAs) at the molecular response in CML adult patients receiving TKIs treatment. A total of 86 samples were collected, 30 from CML patients responsive and 28 from non-responsive to imatinib therapy, and 28 from blood donors. NGS was conducted whereby 18 miRNAs were selected and validated by real-time RT-qPCR in triplicate.

Results: Hsa-miR-181a-5p was expressed significantly (p-value < 0.05) with 2.14 and 2.33-fold down-regulation in both patient groups, respectively meanwhile hsa-miR-182-5p and hsa-miR-26a-5p were significant only in the non-responsive group with 2.08 and 2.39 fold up-regulation. The down-regulation was consistent with decreased amounts of BCR-ABL1 in patients taking TKIs regardless of molecular responses. The up-regulation was consistent with the substantial presence of BCR-ABL1 in CML patients treated with TKIs at the molecular response.

Conclusions: Therefore, these miRNAs have potential as new therapeutic biomarkers for BCR-ABL1 status in adult CML patients treated with TKIs at molecular responses. These could improve current approaches and require further analysis to look for targets of these miRNAs in CML.

Keywords: Hsa-miR-181a-5p, Hsa-miR-182-5p, Hsa-miR-26a-5p, Chronic myeloid leukemia, Tyrosine kinase inhibitors, Next generation sequencing

Background

CML occurs mainly in adults with Philadelphia chromosome (Ph) present in most patients [1] as a result of a reciprocal translocation between chromosome 9 and 22 that gives rise to BCR-ABL1 transcripts, t(9;22)
There are 3 phases of CML: chronic, accelerated, and blast crisis; CML is treated using Tyrosine Kinase Inhibitors (TKIs). Imatinib (Glivec®, Novartis), a first-generation TKI, has been widely used since the Food and Drug Administration (FDA) approval in 2001, given orally (400 mg) once daily, and patients in the chronic phase usually respond well to treatment [1, 4, 5]. It is a targeted therapy whereby imatinib competes for the BCR-ABL1 tyrosine kinase site to prevent phosphorylation and inhibit proliferation [6]. Patients treated with imatinib are usually experiencing mild or moderate adverse effects [5].

Treatment progress is measured based on hematologic, cytogenetic, and molecular responses. Complete Hematologic Response (CHR) is when clinical presentations return to normal meanwhile, Complete Cytogenetic Response (CCyR) is when Ph is not detected. A molecular response is the major endpoint with the optimal molecular response at BCR-ABL1 transcript level ≤ 10% by 3 months, ≤ 1% by 6 months is similar to CCyR and ≤ 0.1% by 12 months, known as Major Molecular Response (MMR). Beyond optimal response is known as warning or failure whereby each indicates treatment continuation, carefully considering or changing according to the patient's conditions. Patients non-responsive or intolerant to imatinib will be administered second and third-generation (2G or 3G) TKIs as necessary, whereby nilotinib, dasatinib, and bosutinib, 2GTKIs are now choices of front-line treatment. These enable patients to not only achieve MMR faster but also much deeper molecular responses than imatinib. However, 2G and 3G TKIs showed harsher side-effects and clinical constraints without improved overall survival [4].

The BCR-ABL1 transcripts level quantification is by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). It is a ratio of BCR-ABL1 transcripts to ABL1 transcripts or another internationally accepted control transcript regarding the International Randomized Study of Interferon and STI571 (IRIS) trial. It is referred to as the International Scale (IS). The IRIS standardized baseline is considered as 100% and below this or 1, 0.1, 0.01% (MR4), 0.0032% (MR4.5) and 0.001% (MR5) correspond to 2, 3, 4, 4.5, and 5-log reduction from the IRIS baseline respectively. MR4, MR4.5, and MR5 are known as deep molecular responses (DMR) [6]. A conversion factor converts laboratory ratio to an IS ratio and is determined through sample exchange with an established reference laboratory or calibrated to WHO International Genetic Reference Panel [7].

Patients who achieved DMR (MR4, MR4.5) have a quality of life near the general population; enable cessation studies in suitable patients. It is promising as losing MMR is uncommon after a year in treatment-free remission (TFR) otherwise indicates failure. Based on shared decision making, requirements for TKI discontinuation include first chronic phase, motivated patient, no prior treatment failure, typical e13a2 or e14a2 BCR-ABL1 transcripts, more than 5 years on TKI, and achieved DMR for more than 2 or 3 years for MR4.5 and MR4 respectively [4]. DMR of 4.5-log reduction or lower is preferable for discontinuation of imatinib by controlled studies due to fewer events observed and better clinical outcomes [8–10]. These low-level estimates are measured by using RT-qPCR which gives substantial errors, particularly from Poisson variation, with a limit of detection (LoD) of 10^{-4}, 10^{-4.5}, and below [11–13]. These lead to disagreements in reporting as recommended by EUTOS, particularly in assigning targets to 3 for less than 3 copies [11, 12, 14]. Among suggestions for reporting of the result were to include confidence limit [12], average targets or as an individual result for undetectable replicate [11], and LoD was proposed [15]. In most centres, the routine LoD for RT-qPCR is MR4.5 [16]. All these have compromised the consistency of DMR which could hinder timely TKI discontinuation; therefore, a new therapeutic biomarker is necessary.

MicroRNAs (miRNAs) are small non-protein-coding, endogenous RNAs around 22 nucleotides long and function as regulators in gene expression. The expression could be down-regulated or up-regulated. Mature miRNAs are incorporated in the RNA-induced silencing complex and annealed to mRNA. Regulation of gene expression is by mRNA cleavage or translational repression [17]. miRNAs have been studied extensively in cancer, and studies showed miRNAs have potential as a tumour suppressor or oncogene with potential use in the diagnosis, prognosis, and treatment of cancers [18–25].

NGS is suitable for detecting low-level variants as it allows deep sequencing with high sensitivity and high sequencing coverage. There are several platforms available with unique specifications [26]. Miseq system (illumina®), an easy-to-use NGS instrument that offers short sequencing run times, long read lengths, and high data quality, is suitable for targeted resequencing. The sequencing workflow involves library preparation, cluster generation, sequencing by synthesis, and data analysis. Except for library preparation, the rest are carried out by the instrument making it a reliable platform.

In this study, we investigate miRNAs of adult CML patients, responsive and non-responsive to imatinib therapy at the molecular response. Imatinib is the front-line treatment used to treat CML, and in the event of intolerance or failure, other approved TKIs are an option as appropriate. Current treatment success is measured by the minimal presence or undetectability of BCR-ABL1.
transcripts by RT-qPCR. miRNAs from the whole blood of these patients were profiled using NGS and compared with normal control. miRNAs suitable for the study were selected and verified by real-time RT-qPCR, the known gold standard for quantifying gene expression. Therefore, this study aimed to identify miRNAs that have therapeutic potential concerning TKIs at the molecular response in CML. These miRNAs could lead to discovering conditions that favour TKI discontinuation accurately, thus making long-term TFR achievable.

**Methods**

**Patients and samples**

A cross-sectional study was conducted among adults aged 18 and above in Ampang Hospital and National Blood Centre (NBC) Malaysia between 2013 and 2014. Of these respondents, 30 were CML patients responsive to imatinib therapy, and 28 were CML patients non-responsive to imatinib therapy taken from Ampang Hospital, while 28 were blood donors mostly from NBC. Peripheral blood samples were collected from all the respondents. A standardized data collection form was used to collect information from the respondents. The collection form has three domains that were sociodemographic information, treatment history with imatinib, and treatment status responsive or non-responsive. Responsive is defined as a CML patient assessed and confirmed by the clinician through clinical diagnostics and evaluations, receiving imatinib not less than 18 months, the latest BCR-ABL1 ratio was 0.1% or less and ABL1 control gene equalled 10,000 copies or more. Non-responsive, defined as any of the above criteria that are not met and treated with imatinib, other TKIs, or other drugs as necessary. Control, defined as normal people taken from healthy donors, mostly was from the NBC who came to donate blood. The lab used a conversion factor of 0.81 to convert the BCR-ABL1 ratio to the IS ratio. Blood samples and clinical data were collected from the clinic and sent to the research laboratory.

**Preparation of samples**

Peripheral blood (2.5 ml) was collected from each participant using BD® Vacutainer Safety-Lok™ Blood Collection Set and drawn into PAXgene® Blood RNA tube (PreAnalytiX). Purification of total RNA including miRNA was conducted using; PAXgene® Blood miRNA Kit (PreAnalytiX) with silica-membrane technology. The quantity of total RNA was measured by NanoDrop® ND-1000 spectrophotometer. Meanwhile, the quality of total RNA and small RNA were analysed by the 2100 Bioanalyzer (Agilent) using Eukaryote Total RNA Nano assay (Agilent) for RNA Integrity Number (RIN) and Small RNA assay (Agilent) for the amount (%) of miRNA.

**Next generation sequencing**

Total RNA of a CML patient responsive to imatinib therapy with RIN 7.7, a CML patient non-responsive to imatinib therapy with RIN 7.4, and a normal control with RIN 8.1 were selected for NGS. TruSeq Small RNA kit (illumina®); was used to prepare libraries for subsequent cluster generation. A library was generated from each sample and labelled using a unique index sequence each. The kit contained adapters designed to directly and specifically ligate to a 5’-phosphate and a 3’-hydroxyl group of mature miRNAs. The ligated small RNA was reverse transcribed and amplified with a unique index per tube to create cDNA constructs according to the protocol (Catalogue # RS-930-1012, Part # 15004197 Rev. C, March 2011). The cycling conditions for PCR amplification were 30 s at 98°C, 15 cycles of 10 s at 98°C, 30 s at 60°C, and 15 s at 72°C, followed by 10 min at 72°C and hold at 4°C. Each sample was analysed using High Sensitivity DNA assay (Agilent) and obtained around 150 bp band and peak each at a 100x dilution.

The cDNA constructs (library) were purified using 6% Novex TBE PAGE Gel, 1.0 mm (Invitrogen). Libraries with unique indexes were pooled, added Novex DNA Loading Dye (Invitrogen), and loaded into 2 wells (25 μl each). The gel ran for 60 min at 145 V in the XCell SureLock™ Mini-Cell electrophoresis unit (Invitrogen®) containing 1X TBE buffer. Upon completion, the gel was removed and stained with 0.5 mg/ml ethidium bromide solution for 2 to 3 min. It was viewed under UV light, and bands between 160 and 145 bp were cut out using a razor blade. The excised gel fragment was passed through a 0.5 ml Gel Breaker tube by centrifugation, added 300 μl of Ultra-Pure water, passed through a 5 μm Filter tube by centrifugation, and concentrated by ethanol precipitation. The pellet was then resuspended in 10 μl 10 mM Tris-HCl, pH 8.5, and kept at −15°C to -25°C. The purified sample library (different indexes) was validated using Agilent’s DNA 1000 assay (obtained a single sample peak around 150 bp) and High Sensitivity DNA assay (diluted 100x and obtained 152bp peak, 1500pmol/l) measured using the 2100 Bioanalyzer (Agilent).

The purified sample library was normalized to a 4 nM library using 10 mM Tris-CI pH8.5 with 0.1% tween 20, denatured to a 20 pM library in 1 mM NaOH using 0.2 N NaOH and pre-chilled HT1, and diluted to 13 pM using pre-chilled HT1. These were prepared according to Preparing Libraries for Sequencing on the MiSeq guide: Part # 15039740 Rev.D October 2013 (illumina®). The supplied 10 nM PhiX library was diluted to 4 nM using 10 mM Tris-CI pH8.5 with 0.1% tween 20, denatured to 20 pM, and further diluted to 12.5 pM. The denatured and diluted PhiX control was spiked in at least 5% to the purified sample library. The libraries were then dispensed
into sample reservoir of reagent cartridge according to MiSeq® Reagent Kit v2 (50 cycles) Reagent Preparation Guide (illumina®) and ran on Miseq (illumina, USA) using Standard Flow Cell with 14 tiles imaged top and bottom for 15 M reads (approximately 5 M reads per sample). Clusters were generated and sequenced by synthesis with a single read, and then were imaged using LED and filter combinations meant for each fluorescently-labelled nucleotide. BaseSpace (illumina®) aligned, assembled, and analysed the reads. miRNAs of the responsive sample and miRNAs of the non-responsive sample were compared to miRNAs of the normal control. Eighteen miRNAs were selected mainly with regards to substantial expression level and clinical significance.

**Real-time reverse transcriptase-quantitative PCR (RT-qPCR)**

The selected miRNAs were ordered as ready-to-use 96-well plate Custom miScript™ miRNA PCR Array (Qiagen). The array plate consisted of the 18 miRNAs, normalisation controls (SNORD61, SNORD95, SNORD96A, RNU6–2), reverse transcription control (miRTC), and positive PCR control (PPC) in the 24 × 4 format. cDNA was prepared using miScript® II RT kit (Qiagen) for a 20 μl reaction. The reaction consisted of 4 μl 5x miScript HiSpec Buffer, 2 μl 10x miScript Nucleic Mix, 2 μl miScript Reverse Transcrptase Mix, RNase-free water, and template RNA. A starting input of 250 ng total RNA (containing miRNA) was used as recommended, which will result in 0.5 to 1 ng cDNA per array well. The reaction was incubated for 60 min at 37 °C, followed by 5 min at 95 °C, and placed on ice. The 5x miScript HiSpec buffer facilitated the conversion of mature miRNAs into cDNA while suppressing long RNAs.

miScript® SYBR® Green PCR kit (Qiagen); was used with our 96-well plate Custom miScript™ miRNA PCR Array. A reaction mixture consisted of 1375 μl 2x QuantiTect SYBR® Green PCR Master Mix, 275 μl 10x miScript Universal Primer, 1000 μl RNase-free water, and 100 μl template cDNA. Out of this, 25 μl per well was added to the verified array plate. Then the array plate was placed in Light Cycler 480 (Roche), a real-time cycler. The cycling conditions used were: initial activation for 15 min at 95 °C, 45 cycles of; denaturation for 15 s at 94 °C followed by annealing for 30 s at 55 °C, and extension for 30 s at 70 °C. PCR amplification was followed by dissociation curve analysis performed for 10 s at 95 °C, 1 min at 65 °C, and a continuous 95 °C. The miScript PCR system used; allowed sensitive and specific detection and quantification of the mature miRNAs in triplicate in all case and control samples.

A threshold value of 1.15 was used across all PCR runs and obtained threshold cycle (C_T) of PPC (C_T^PPC) value equivalent to 19 ± 2 and C_T^miRTC. C_T^PPC value less than 7, thus allowing comparison of results. These indicated high-quality RNA samples, correct cycling program run, and the correct threshold was used, and no apparent inhibition of the reverse-transcription reaction occurred, respectively. In addition, a single melting peak was exhibited in each sample representing a specific PCR product. The Light Cycler uses a crossing point with the Fit Points method while Gene Globe Data Analysis Centre (Qiagen) uses C_T which is similar. Data was formatted in an Excel Spreadsheet using a provided template and uploaded into the Gene Globe Data Analysis Centre in a web browser (Qiagen). Normalisation was conducted using the Global Threshold Cycle Mean of expressed miRNAs. Relative quantification was performed using ΔΔC_T method; whereby ΔC_T = C_T^miRNA - C_T normalisation factor, while ΔΔC_T = ΔC_T (experimental sample) – ΔC_T (control sample). Fold change was calculated as 2^ΔΔC_T whereby greater than 1 was reported as fold up-regulation while less than 1 as fold down-regulation. P-values were calculated based on the Student’s t-test of the replicate 2^(-ΔΔC_T) values for each miRNA. Any significant miRNA observed will be linked to TKIs received and the clinical outcomes of patients.

**Results**

The majority of the respondents were Malays (51%), followed by Chinese (34%) and Indians (15%). There were more males than females in this study. The hallmark of CML (BCR-ABL1 transcript) was present in all patients who were diagnosed with CML. In responsive patients, BCR-ABL1 ratios showed a declining pattern with imatinib therapy. Common chromosomal abnormalities; usually seen with CML were observed such as; trisomy 8, which was seen in responsive and non-responsive patients. Loss of chromosome Y, an age-related chromosomal abnormality, was seen in Ph-negative older male patients. This study showed that the number of responsive and non-responsive patients was similar in Malays. The responsiveness is markedly higher among the Chinese. However, the numbers of Indian respondents were too small for comparison (Table 1).

In responsive patients, 53% achieved MMR of 7 Malays, 6 Chinese, and 3 Indians. The remaining 47% achieved DMR of 6 Malays, 6 Chinese, and 2 Indians, in which 40% were with 4-log reduction (MR4) and 7% with 4.5-log reduction (MR4.5) from the IRIS baseline. Longer duration on imatinib of around 6 years (mean ± 34.50 months) was observed in DMR patients compared to about 5.5 years (mean ± 30.43 months) in MMR patients. Overall mean duration on imatinib was 5.7 years with 53% being on imatinib for more than 5 years (Table 2). In non-responsive patients, imatinib was changed to other TKIs (82%) or other treatment
options (11%) according to mutations in the kinase domain and patients’ conditions and tolerability. BCR-ABL1 IS ratio was < 0.1% in 29% of patients, and the average of the latest available BCR-ABL1 IS ratio was 13.7% (Table 3).

Profiles of miRNA expression by NGS showed a similar amount of mature miRNA was present in all samples, with 40.8% in normal control, 40.9% in responsive sample, and 40.3% in the non-responsive sample. A list of miRNAs with various expression levels was generated from each patient sample and compared to normal control. Among these, hsa-miR-181-5p expressed 0.45 and 0.51 times in responsive and non-responsive samples respectively.

These were consistent with real-time RT-qPCR data whereby significant down-regulations of hsa-miR-181-5p were observed in both responsive (Group 1) and non-responsive (Group 2) groups when compared to the control group (Figs. 1 and 2 respectively). Fold change of hsa-miR-181a-5p was 0.47 (95% CI = 0.36, 0.58, p-value = 0.000006 that was < 0.05) in responsive group (Fig. 3) and 0.43 (95% CI = 0.31, 0.55, p-value = 0.000024 that was < 0.05) in non-responsive group (Fig. 4) which corresponded to 2.14 and 2.33 fold down-regulation respectively compared to control group.

In addition, another 2 miRNAs were also significant but only in the non-responsive group. These were hsa-miR-182-5p with fold change of 2.08 (95% CI = 1.60, 2.57, p-value = 0.000012 that was < 0.05) and hsa-miR-26a-5p with fold change of 2.39 (95% CI = 1.82, 2.96, p-value = 0 that was < 0.05) as shown in Fig. 4 which corresponded to 2.08 and 2.39 fold up-regulation respectively when compared to the control group. The statistical analyses of real-time PCR data were as shown in Tables 4 and 5. Comparison of these biomarkers to BCR-ABL1 and IS levels were presented in Tables 2 and 3.

In the responsive group, a reference gene, RNU6–2, a small non-coding RNA, was also significant with fold change of 0.48 (95% CI = 0.37, 0.58, p-value = 0 that was < 0.05) corresponded to 2.10 fold down-regulation when compared to the control group (Fig. 3).

**Discussion**

We looked at our CML patients concerning imatinib therapy, a front-line treatment for CML in our government hospitals; because of treatment discontinuation for optimal CML responders as suggested by the European LeukemiaNet (ELN) 2013 and also ELN 2020. Data showed that half of our responsive patients received imatinib therapy for more than 5 years with a mean age of 48 years old, an average of 5.5 years for patients with MMR, and 6 years for DMR. These indicated on average, MMR achieved by 18 months

### Table 1 Demographic characteristic of CML patients responsive and non-responsive to imatinib therapy and blood donors

| Characteristic | Imatinib Responsive Group (n = 30) | Imatinib Non-Responsive Group (n = 28) | Control Group (n = 28) |
|---------------|-----------------------------------|---------------------------------------|------------------------|
| Ethnicity:    |                                   |                                        |                        |
| Malays        | 13 (43%)                          | 16 (57%)                              | 15 (53%)               |
| Chinese       | 12 (40%)                          | 7 (25%)                               | 10 (36%)               |
| Indians       | 5 (17%)                           | 5 (18%)                               | 3 (11%)                |
| Gender:       |                                   |                                        |                        |
| Male          | 17 (57%)                          | 13 (46%)                              | 22 (79%)               |
| Female        | 13 (43%)                          | 15 (54%)                              | 6 (21%)                |
| Age (year):   |                                   |                                        |                        |
| 18 - < 45     | 13 (43%)                          | 11 (39%)                              | 22 (79%)               |
| ≥ 45          | 17 (57%)                          | 17 (61%)                              | 6 (21%)                |
| Mean ± std. dev | 48 ± 13                          | 46 ± 14                               | 36 ± 9                 |

### Table 2 Clinical findings of CML patients responsive to imatinib therapy and a potential biomarker at the molecular response

| Total No | Age (year) | Duration on imatinib (month) | IRIS molecular response (BCR-ABL1 IS) | Relative expression of hsa-miR-181a-5p (fold regulation) (collectively = 2.14 down-regulation) |
|----------|------------|------------------------------|---------------------------------------|------------------------------------------------------------------------------------------------|
| 16       | 25–75      | 26–122                       | MMR (≤ 0.1% or ≥ 3-log reduction)     | -5.5987 to 1.2789                                                                                  |
| 12       | 40–71      | 20–131                       | MR (≤ 0.01% BCR-ABL1 IS or undetectable with 10,000–31,999 ABL1 transcripts) | -8.664 to -1.0906                                                                                 |
| 2        | 32–54      | 24–50                        | MR (≤ 0.0032% BCR-ABL1 IS or undetectable with 32,000–99,999 ABL1 transcripts) | -2.5939 and -1.7594                                                                               |
| 30       | 25-75      | 20-131                       | MMR (≤ 0.1% or ≥ 3-log reduction)     | -5.5987 to 1.2789                                                                                  |

*a* International Scale  
*b* comparing to control group  
*c* Range  
*d* mean ± sd
extended survival for at least 4 years, and DMR is achievable with a longer time on therapy in our CML patients. DMR was observed in almost half of the responsive patients, and if consistent, these patients can be considered for imatinib discontinuation studies, as minimum requirements are at least 24 months of DMR [4], and previously 12 months of DMR [27]. DMR was reported suitable for imatinib discontinuation as it has survival benefits and lesser events [8]. However, determining the right time for imatinib discontinuation is critical. Long-term TFR is still low, with relapse after discontinuation being considerably high in remission patients. The weighted mean molecular relapse rate of CML was 42%, and mean molecular remission was more than 37 months before discontinuation of imatinib. A shorter duration of imatinib therapy and a shorter time with an undetectable level of BCR-ABL1 transcripts were reasons for relapse [28]. Therefore sufficient time on imatinib and consistency in DMR is crucial before imatinib discontinuation.

Management of CML has remarkably improved over the years with a high success rate for treatment using TKIs in chronic patients. This is assisted by new analysis techniques complementing existing ones for comprehensive detection and monitoring of CML. RT-qPCR, a sensitive technique has become a gold standard in the molecular response and is used to analyse treatment response, especially from TKIs as the first line. Since RT-qPCR has limitations at very low-levels thus new biomarkers are needed not only to assist analysis but also to understand better molecular and cellular interactions and associations to prolong TFR.

Numerous novel findings; were reported from CML studies using NGS, a new technology with relatively high sensitivity and high coverage. In CML patients treated with imatinib, NGS has enabled identification of novel BCR-ABL1 fusions gene comprising BCR intron 14 and ABL1 intron 2 breakpoints, giving partial deletion of SH3 domain [29]. Meanwhile, with whole-genome sequencing, NGS has enabled identification of e13a2-like BCR-ABL1 fusion comprising broken BCR exon 13 and 9 ABL1 intron 1 nucleotides forming a novel chimeric exon [30]. In our study, NGS has assisted in identifying miRNAs at the molecular response in local CML patients responsive and non-responsive to imatinib therapy. Validation by custom array real-time RT-qPCR has identified hsa-miR 181-5p, hsa-miR-182-5p, and hsa-miR-26a-5p as potential new therapeutic biomarkers in response to treatment using TKIs in CML. Hsa-miR-181-5p could be a tumour suppressor miRNA and might be involved in major or partial suppression of CML. Meanwhile, hsa-miR-182-5p and hsa-miR-26a-5p could be oncomiRs in which their expressions may indicate non-responsiveness to TKIs treatment or relapse.

Hsa-miR-181a-5p was significantly down-regulated in both the responsive and non-responsive to imatinib groups compared with the control group. The down-regulation indicated significant interactions between hsa-miR-181a-5p and TKI therapies. These showed that imatinib, nilotinib, dasatinib, and bosutinib were taken by CML patients, over time had caused inhibition to CML cell proliferation, led to apoptosis, and thus reduced the amount of BCR-ABL1 in CML.

### Table 3 Clinical findings of CML patients non-responsive to imatinib therapy and potential biomarkers at the molecular response

| Total No | Age (year) | Duration on TKIs (month) | IRIS molecular response (BCR-ABL1) | Relative expression<sup>b</sup> of hsa-miR-181a-5p (fold regulation) | Relative expression<sup>b</sup> of hsa-miR-182-5p (fold regulation) | Relative expression<sup>b</sup> of hsa-miR-26a-5p (fold regulation) |
|----------|------------|--------------------------|------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| 7        | 20–64      | 13–142                   | > 10%                              | −41.3405 to 2.0286                                                              | −2.3320 to 9.5690                                                              | −2.9519 to 12.6264                                                            |
| 5        | 43–64      | 47–92                    | ≤ 10%                              | −6.5409 to −1.3561                                                              | −1.5069 to 1.9297                                                              | −1.4556 to 2.6728                                                            |
| 6        | 22–49      | 11–58                    | ≤ 1%                               | −4.3154 to −1.0566                                                              | −1.1031 to 2.8252                                                              | −1.5819 to 3.2229                                                            |
| 5        | 21–64      | 35–131                   | ≤ 0.1%                             | −4.4367 to −1.3009                                                              | −1.1108 to 4.3120                                                              | −1.3581 to 11.0684                                                           |
| 2        | 36–61      | 29–109                   | MR<sup>4</sup>                     | −1.9178 and 1.0501                                                              | 4.0233 and 5.8904                                                              | 5.8497 and 7.4559                                                            |
| 2        | 42–60      | 26–75                    | MR<sup>6</sup>                     | −2.3776 and 1.1333                                                              | 1.1474 and 7.1027                                                              | 1.1083 and 2.7102                                                            |
| 1        | 64         | 65                       | undetermined                       | 1.5916                                                                          | 8.1589                                                                         | 13.9131                                                                      |
| 28       | 20–64<sup>c</sup> (46.04 ± 14.25)<sup>d</sup> | 11–142<sup>c</sup> (61.86 ± 36.33)<sup>d</sup> | | | | |

<sup>a</sup> International Scale
<sup>b</sup> comparing to control group
<sup>c</sup> Range
<sup>d</sup> mean ± sd
patients. The down-regulation observed in the responsive to imatinib group represented 3 to 4.5-log reduction (MMR to MR4.5) of BCR-ABL1 levels from the IRIS baseline with an average of 5.7 years of intake. Similarly, down-regulation observed in the non-responsive to imatinib group represented less than 1 to 5-log reduction (approaching MMR to MR5) of BCR-ABL1 levels from the IRIS baseline. These down-regulations of hsa-miR-181a-5p indicated a positive correlation to log reduction or reduced levels of BCR-ABL1 in CML patients treated with TKIs. Therefore hsa-miR-181a-5p has the potential to be used as a therapeutic biomarker for the positive performance of TKIs shown by reduced levels of BCR-ABL1 indicating patients were responding to TKIs treatment in CML. Hsa-miR-181a-5p could be a tumour-suppressive miRNA that prevents mRNA
from coding specific protein directly or associated with CML in patients treated with TKIs.

On the other hand, hsa-miR-182-5p and hsa-miR-26a-5p were significantly up-regulated in the non-responsive to imatinib group compared with the control group. The fold up-regulation was 2.08 and 2.39, respectively, and was observed only in this group. These were patients whereby most of their latest available BCR-ABL1 ratios were more than 0.1% that was neither in MMR nor did DMR, with a substantial average, and only 7% [2] treated with imatinib. Fold regulation of these miRNAs in the imatinib responsive group, whereby BCR-ABL1 in these patients was minimal or absent (MMR or DMR), was not significant compared with the control group. It indicated imatinib had reduced the amount of BCR-ABL1 in these responsive patients to the
extent not significantly different compared with healthy donors. Thus the significant up-regulation could indicate that hsa-miR-182-5p and hsa-miR-26a-5p have a positive correlation to the substantial presence of BCR-ABL1 in CML patients treated with TKIs. Therefore, these miRNAs could function as new therapeutic biomarkers for the substantial presence of BCR-ABL1 in CML patients treated with TKIs. Hsa-miR-182-5p and hsa-miR-26a-5p could be oncogenic miRNAs (oncomiRNAs) and might be associated with CML in patients treated with TKIs.

Studies have shown hsa-miR-181a-5p as a therapeutic biomarker, has potential use for clinical improvement in cancers. It is demonstrated in gastric cancer cells whereby hsa-miR-181a-5p has been extensively studied and reported as a potential regulator of MEG2, a tumour suppressor gene [31], regulated RASSF6, and in combination predicts poor prognosis in gastric cancer [32]. It also inhibited MTMR3 expression in AGS gastric cancer cells and was identified as novel autophagy [33]. In non-small-cell-lung cancer tissues and cell lines, hsa-miR-181a-5p was reported significantly reduced and has a potential role in tumour suppression by partially targeting Kras [34], a protein that regulates cell growth. In breast (BC) and colon cancers (CC), hsa-miR-181a-5p was reportedly down-regulated and inversely related to matrix metalloproteinase-14, which is elevated in tumours, in which, to prevent cancer metastasis in BC and CC, is by elevating hsa-miR-181a-5p [35]. In hepatocellular carcinoma: miR-181 was reported to significantly turn on the MAPK/JNK pathway, the regulator of cell proliferation, and by limiting it, would suppress the pathway [36]. Hsa-miR-181a-5p, a tumour suppressor is considered as a prognostic marker in Acute Myeloid Leukemia patients treated with intensive induction chemotherapy and autologous stem cell transplant [37].

Higher expression of hsa-miR-182-5p as observed in our study was also seen in other studies as in prostate cancer (PCa); lung squamous cell carcinoma tissues analysed from The Cancer Genome Atlas database, the Gene Expression Omnibus database, and real-time qPCR [38];
and also in colorectal cancer cells using tumorigenic variant cell line MICOL-14<sup>tum</sup> compared to MICOL-14<sup>h-tert</sup> cells [39]. In PCa, the biphasic role of hsa-miR-182-5p was observed, with a higher expression in localized PCa and contrarily lower expression in aggressive cancers [40]. Lower expression was also observed in renal cancer whereby hsa-miR-182-5p was down-regulated in tumour tissue compared with adjacent normal tissues, and over-expression decreased tumour growth in mice, demonstrating antitumor effect [41].

Hsa-miR-26a-5p expression in our study is consistent with a bigger-sample size study than ours on CML patients indicating the expression of miR-26a is influenced by the response to TKIs used [42]. The study

**Fig. 4** Lower expression of hsa-miR-181a-5p of 0.43 was also observed in Group 2 (CML patients non-responsive to imatinib therapy) compared with the Control Group (blood donors) by real-time RT-qPCR (p-value < 0.05). In addition, higher expressions were only observed from hsa-miR-182-5p and hsa-miR-26a-5p of 2.08 and 2.39, respectively, in this group.
| Mature ID      | Average Ct | Standard Deviation | Control Group | Standard Deviation | Group 1 | Standard Deviation | Control Group | Standard Deviation | Group 1 | Standard Deviation | Control Group | Group 1 |
|---------------|------------|--------------------|---------------|-------------------|---------|--------------------|---------------|-------------------|---------|--------------------|---------------|--------|
| hsa-miR-181a-5p | 24.99      | 0.804605           | 25.86         | 0.764923          | 5.146885| 0.734814           | 6.241981      | 0.588011          | 0.028225| 0.013212           | 0.028225      | 0.013212|
| RNU6–2        | 20.06      | 0.828910           | 20.90         | 0.754208          | 0.212599| 0.0610294          | 1.281648      | 0.640244          | 0.862981| 0.411325           | 0.862981      | 0.411325|

Table 4 Normalized expressions ($2^{\text{Avg.}(\text{Delta}(\text{Ct}))}$) of hsa-miR-181a-5p and RNU6–2 in Group 1 (CML patients responsive to imatinib therapy), and Control Group (blood donors) calculated by Gene Globe Data Analysis Centre (QIAGEN)
Table 5  Normalized miRNA expression ($2^{(-\text{Avg.(Delta(Ct))})}$) in Group 2 (CML patients non-responsive to imatinib therapy) and Control Group (blood donors) of significant miRNAs calculated by Gene Globe Data Analysis Centre (QIAGEN)

| Mature ID | Average Ct | Standard Deviation | Group 2 | Standard Deviation | Average Delta(Ct) (Ct(miROI) - Average Ct(normalisation factor)) | $2^{(-\text{Average(Delta(Ct))})}$ |
|-----------|------------|--------------------|---------|--------------------|----------------------------------------------------------------|--------------------------|
|           |            | Control Group      | Group 2 |                    | Control Group | Standard Deviation | Group 2 | Standard Deviation | Control Group | Group 2 |
| hsa-miR-181a-5p | 24.99      | 0.804605           | 26.01   | 1.340582           | 5.146885       | 0.734814           | 6.366369 | 0.836165           | 0.028225      | 0.012121 |
| hsa-miR-182-5p  | 23.46      | 0.811293           | 22.21   | 1.120019           | 3.621528       | 0.636088           | 2.563155 | 0.647466           | 0.081248      | 0.169205 |
| hsa-miR-26a-5p  | 21.11      | 0.829467           | 19.65   | 1.452098           | 1.264028       | 0.409326           | 0.005655 | 0.833271           | 0.416380      | 0.996088 |
showed miR-26a was differentially expressed; in HL-60, BCR-ABL cells when treated with tyrosine kinase inhibitors when compared to HL-60 cells. miR-26a expression levels increased gradually with both dasatinib and nilotinib treatments. The increased expression levels with dasatinib and nilotinib were consistent with our findings of hsa-miR-26a expression was up-regulated in CML patients molecularly non-responsive to imatinib compared with controls whereby most patients were treated with nilotinib or dasatinib. Thus, with dasatinib and nilotinib treatments, up-regulation of hsa-miR-26a was observed in CML patients’ non-responsiveness to imatinib. However, HL-60, BCR-ABL cells treated with imatinib mesylate showed increased miR-26a expression at 4-h but decreased expression at 8-h. It correlates with miR-26a expression was lower in chronic phase patients (62.5% Complete Cytogenetic Response (CCyR) and 37.5% imatinib-resistant) when compared with healthy individuals. miR-26a expression was also lower in imatinib-resistant patients when compared to patients who achieved CCyR (< 1% BCR-ABL1) [43]. Hsa-miR-26a-5p expression in our study was not significant in CML patients molecularly responsive to imatinib compared with controls as these were patients either in MMR or DMR (≤ 0.1% to undetectable BCR-ABL1). These showed that with imatinib, expressions of hsa-miR-26a were decreasing from responsiveness towards resistance. Thus these expressions indicated that imatinib, nilotinib, and dasatinib had altered BCR-ABL kinase activity differently.

The main limitation of this study was the low number of patient samples collected, which was due to only a small number of patients fulfilling all the required criteria within the 2-year duration. Hence, a longer time of sample collection is appropriate. In addition, our custom plate of 4 × 24 introduced variations between plates for replicates on different array plates. It made determining a suitable threshold challenging. Instead, using an array plate of 3 × 32 for triplicate is recommended.

These studies showed that hsa-miR-181a-5p, hsa-miR-182-5p, and hsa-miR-26a-5p are promising therapeutic biomarkers and can be manipulated to improve cancer treatment. In this study, only 18 miRNAs from NGS profiles were validated using real-time RT-qPCR; thus the significant miRNAs observed could be solely or partially involved in the decreasing and or increasing of BCR-ABL1 in CML patients. Further studies are needed to determine their targets and the effect of involvement in CML. Knowing their interactions and targets in CML will give their net effects that allow manipulation by inhibiting oncomiRs or stimulating tumour suppressor miRNAs. These will give new values for TKIs responses which could assist in determining the accurate time for TKIs discontinuation and better prediction of relapse in CML. Timely discontinuation of TKIs in CML remission patients is crucial for long-term TFR. Prolong TFR would subsequently allow CML patients to achieve a good quality of life as healthy people.

Conclusions
Hsa-miR-181a-5p has the potential as a therapeutic biomarker for BCR-ABL1 at below current LoD in CML adult patients treated with TKIs at the molecular response and could be a tumour-suppressive miRNA. Meanwhile, hsa-miR-182-5p and hsa-miR-26a-5p have potential as therapeutic biomarkers for the substantial presence of BCR-ABL1 in CML adults and could be oncomiRNAs.

Abbreviations
TKI: Tyrosine Kinase Inhibitor; CML: Chronic Myeloid Leukemia; TFR: Treatment free remission; NGS: Next Generation Sequencing; RT-qPCR: Reverse transcriptase-quantitative PCR; miRNA: MicroRNA; Ph: Philadelphia chromosome; IRIS: International Randomized Study of Interferon and STI571; IS: International Scale; DMR: Deep Molecular Response; CCyR: Complete Cytogenetic Response; LoD: Limit of Detection; RIN: RNA Integrity Number; PPC: Positive PCR Control, miRTC: Reverse Transcription Control; CT: Threshold Cycle; ELN: European LeukemiaNet; BC: Breast Cancer; CC: Colon Cancer; PCa: Prostate Cancer.

Acknowledgments
We would like to thank the Director-General of Health Malaysia for his permission to publish this article, the Director of Institute for Medical Research for his technical support, respondents and assisting staff from Hospital Ampang and National Blood Centre, Malaysia, Arna Shahrif Azali and Muhammad Asyraf Noh for their comprehensive samples and clinical data collection.

Authors’ contributions
AMY was actively involved in all aspects of the study except for the clinical selection of patients, epidemiology, and biostatistics analysis, and was a major contributor in writing the manuscript, NAM involved in epidemiology and biostatistics research designed and critically reviewed the manuscript, CKM selected suitable CML patients for the study, HAH contributed in NGS preparation and reviewed the manuscript, YMY reviewed hematopathology analysis of the manuscript, and LI reviewed molecular analysis of the manuscript. All authors read and approved the final manuscript.

Funding
This work was supported by a Research Grant from the Ministry of Health, Malaysia (NMRR 12–926-13248). The funding body had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
All procedures performed involving human participants were approved by the Medical Research and Ethics Committee (Ministry of Health Malaysia, P12–837), in accordance with the ethical standards of the institutional and national research committee, and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Written informed consent was obtained from all the respondents in the study before blood collection.
Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Haematology Department, Cancer Research Centre, Institute for Medical Research, National Institutes of Health, Ministry of Health, U13/52 Setia Alam, 40170 Shah Alam, Selangor, Malaysia. 2 Sector for Evidence Based Healthcare, National Institutes of Health, Ministry of Health, Shah Alam, Selangor, Malaysia. 3 Haematology Department, Hospital Ampang, Ministry of Health, Ampang, Selangor, Malaysia. 4 Molecular Pathology Unit, Cancer Research Centre, Institute for Medical Research, National Institutes of Health, Ministry of Health, Shah Alam, Selangor, Malaysia. 5 Special Research Centre, Institute for Medical Research, National Institutes of Health, Ministry of Health, Shah Alam, Selangor, Malaysia.

Received: 15 September 2020   Accepted: 9 March 2022
Published online: 26 March 2022

References

1. Alkkan M, Gale RP, Apperley JF, Foroni L. Molecular techniques for the personalised management of patients with chronic myeloid leukaemia. Biomed Detect Quantif. 2017;11:4–20.

2. Heisterkamp N, Stam K, Groffen J, de Klein A, Grosveld G. Structural organization of the bcr gene and its role in the Ph translocation. Nature. 1985;315(6022):758–61.

3. Cagaani E, Steiner-Saltz D, Aghai E, Gale RP, Berrebi A, Januszewicz E. Altered transcription of an oncogene in chronic myeloid leukaemia. Lancet. 1984;323(8779):593–5.

4. Hocchhaus A. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukaemia. Leukemia. 2020;34:9366–84.

5. Pretel-Irazabal M, Tuneu-Valls A, Ormaechea-Pérez N. Adverse skin effects of Imatinib. a tyrosine kinase inhibitor. Actas Dermosifiliográficas. 2014;105(7):655–62.

6. Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest. 2000;105(1):13–7.

7. Cross NCP, White HE, Colomer D, Ehrencrona H, Foroni L, Gottardi C, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy. Haematologica. 2014;99(3):458–64.

8. Eady R, Kline JS, Mrazek MM. The BCR-ABL1 fusion gene, diagnostic and prognostic marker for osteosarcoma. J Bone Oncol. 2016;5(2):74–9.

9. Chen S, Sun KX, Liu B-L, Zong Z-H, Zhao Y. MicroRNA-505 functions as a tumor suppressor in endometrial cancer by targeting TGF-β1. Mol Cancer. 2016;15(1):11.

10. Wei Z, Liu Y, Wang Y, Zhang Y, Luo Q, Man X, et al. Downregulation of Foxo3 and TRM31 by miR-551b in side population promotes cell proliferation, invasion, and drug resistance of ovarian cancer. Mol Oncol. 2016;10(1):126.

11. Young SS, Tucker T, Boixet I, Karsan A. Estimating deep molecular responses following treatment for chronic myeloid leukemia. Leukemia. 2016;30(7):1620–1.

12. Ma L, Reinhardt F, Pan E, Soutochek J, Bhat B, Marcussen EG, et al. Thera- peutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol. 2010;28(6):341–7.

13. Lang E, Kim E, Son H-Y, Lim E-K, Lee H, Choi Y, et al. Nanoevescence-mediated systemic delivery of microRNA-34a for CD44 overexpressing gastric cancer stem cell therapy. Biomaterials. 2016;105:12–24.

14. Dong J, Liu Y, Liao W, Liu R, Shi P, Wang L. miRNA-223 is a potential diagnostic and prognostic marker for osteosarcoma. J Bone Oncol. 2016;5(2):74–9.

15. Li Y, Kuscu C, Banach A, Zhang Q, Pulkoski-Gross A, Kim D, et al. Novel microRNA-34a is a novel microRNA that controls IGBP1 expression and is associated with malignant progression of lung adenocarcinoma. Cancer Sci. 2017;108(3):536–42.

16. Bandi V, Baluchamy S. miR-181a-2 downregulates the E3 ubiquitin ligase CUL4A transcript and promotes cell proliferation. Med Oncol. 2017;34(8):146.

17. Quail M, Smith ME, Coupland P, Otto TD, Harris SR, Connor TR, et al. A tale of three next generation sequencing platforms: comparison of ion torrent, pacific biosciences and illumina MiSeq sequencers. BMC Genomics. 2012;13(1):341.

18. Hughes TR, Ross DM. Moving treatment-free remission into mainstream clinical practice in CML. Blood. 2016;128(1):17–23.

19. Campiotti L, Basilio M, Guasti L, Rizzi A, Gambiacci-paraserini C, Maria A. Imatinib discontinuation in chronic myeloid leukemia patients with undetectable BCR-ABL transcript level - a systematic review and a meta-analysis. Eur J Cancer. 2017;77:48–56.

20. Li Y, Zhang D, Jiang W, Weng J, Zhou C, Huang K, et al. miR-181a-2 promotes the progression of gastric cancer via RASSF6-mediated MAPK signalling activation. Cancer Lett. 2017;389:11–22.

21. Li Y, Zuo F, Sun F, Hong Y, Liu Y, Fan M, Yin K, et al. MEG2 is regulated by miR-181a-5p and functions as a tumour suppressor gene to suppress the proliferation and migration of gastric cancer cells. Mol Cancer. 2017;16(1):133.

22. Lu Z, Zhang Y, Jiang W, Bi H, Quan L, Wang L. miR-205 and its target genes in chronic myeloid leukemia: ensuring accuracy and consistency. Leukemia. 2015;29(7):1620–1.

23. Cross NCP, Müller MC, Hochhaus A. Response to ho-wan Ip and chi-Chiu. Leukemia. 2015;29(7):1619.
38. Luo J, Shi K, Yin S, Tang R, Chen W, Huang L, et al. Clinical value of miR-182-5p in lung squamous cell carcinoma: a study combining data from TCGA, GEO, and RT-qPCR validation. World J Surg Oncol. 2018;16(1):1–16.

39. Perilli L, Tessarollo S, Albertoni L, Curtarello M, Pastò A, Brunetti E, et al. Silencing of miR-182 is associated with modulation of tumorigenesis through apoptosis induction in an experimental model of colorectal cancer. BMC Cancer. 2019;19(1):1–13.

40. Baumann B, Acosta AM, Richards Z, Deaton R, Sapatynska A, Murphy A, et al. Association of high miR-182 levels with low-risk prostate Cancer. Am J Pathol. 2019;189(4):911–23.

41. Kulkarni P, Dasgupta P, Bhart NS, Shahryari V, Shiina M, Hashimoto Y, et al. Elevated miR-182-5p associates with renal Cancer cell mitotic arrest through diminished MALAT-1 expression. Mol Cancer Res. 2018;16(11):1750–60.

42. Ferreira AF, Moura LG, Tojal I, Ambrósio L, Pinto-Simões B, Hamerschlak N, et al. ApoptomiRs expression modulated by BCR–ABL is linked to CML progression and imatinib resistance. Blood Cells Mol Dis. 2014;53(1–2):47–55.

43. Ferreira AF, Moura LG, Tojal I, Ambrósio L, Pinto-Simões B, Hamerschlak N, et al. Corrigendum to “ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance” [Blood Cells, Mol Dis. 53, (1–2), (June–August 2014) 47–55]. Blood Cells Mol Dis. 2015;55(4):420.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.